(Total Views: 330)
Posted On: 04/23/2019 9:46:35 AM
Post# of 72436
![Avatar](https://investorshangout.com/images/ProfileImages/424989898_3046_Avatar jpeg2.jpg)
Gee, I wonder why some people don't think this qualifies as a huge success?
I wonder. But not very much.
I wonder. But not very much.
Quote:
The Company’s Brilacidin oral rinse demonstrated a strong therapeutic benefit in patients receiving an aggressive chemotherapy regimen (cisplatin administered 80-100 mg/m2, every 21 days), which currently is the standard of care. In this patient population, the incidence of SOM was reduced to 25.0% in the modified Intent-to-Treat (mITT) population, versus 71.4% of patients on placebo. In the Per Protocol (PP) patient group, incidence of SOM dropped to 14.3% for patients receiving Brilacidin oral rinse, compared to 72.7% among those receiving placebo.
The completed Phase 2 study met its primary endpoint, showing a reduction of SOM incidence versus placebo, as well as beneficial treatment effects in reducing the duration of SOM and in delaying the onset of SOM.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)